Barnett & Company’s Novartis NVS Stock Holding History

Barnett & Company’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-402	Closed	-$37K	–	235
2021 Q2	$37K	Hold	402	–	–	0.02%	157
2021 Q1	$34K	Hold	402	–	–	0.02%	185
2020 Q4	$37K	Hold	402	–	–	0.02%	176
2020 Q3	$35K	Hold	402	–	–	0.03%	165
2020 Q2	$35K	Hold	402	–	–	0.03%	149
2020 Q1	$33K	Sell	402 -24	-6%	-$2.14K	0.03%	151
2019 Q4	$40K	Buy	426 +402	+1,675%	+$36.1K	0.02%	184
2019 Q3	$2K	Buy	+24	New	+$2.15K	﹤0.01%	317
2019 Q1	–	Sell	-662	Closed	-$51K	–	323
2018 Q4	$51K	Hold	662	–	–	0.03%	170
2018 Q3	$51K	Buy	+662	New	+$48.9K	0.02%	182

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Barnett & Company's NVS Position: Q3 2021 in Review

Barnett & Company sold out of Novartis (NVS) in Q3 2021, closing a stake of 402 shares — an estimated $37K sold.

Barnett & Company first reported a position in NVS in Q3 2018 and held it in 10 quarters. The position peaked at $51K in Q4 2018. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

Barnett & Company reported no remaining Novartis position as of Q3 2021 after selling out during the quarter.
Barnett & Company sold 402 Novartis shares in Q3 2021, an estimated $37K.
Barnett & Company first reported a position in Novartis in Q3 2018 and held it in 10 quarters.
Barnett & Company's Novartis position peaked at $51K in Q4 2018.
1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Barnett & Company's 13F filing for Q3 2021, filed 4 Nov 2021.